Comprehensive Gene Mutation Profiling of Circulating Tumor DNA in Ovarian Cancer: Its Pathological and Prognostic Impact

Liquid biopsies from circulating tumor DNA (ctDNA) have been employed recently as a non-invasive diagnostic tool for detecting cancer-specific gene mutations. Here, we show the comprehensive gene mutation profiles of ctDNA in 51 patients with different histological subtypes of stage I–IV ovarian can...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2020-11, Vol.12 (11), p.3382
Main Authors: Noguchi, Tomoko, Iwahashi, Naoyuki, Sakai, Kazuko, Matsuda, Kaho, Matsukawa, Hitomi, Toujima, Saori, Nishio, Kazuto, Ino, Kazuhiko
Format: Article
Language:English
Subjects:
Adenomatous polyposis coli
Biopsy
Cancer therapies
Chemotherapy
Colorectal cancer
Deoxyribonucleic acid
DNA
DNA fingerprinting
DNA sequencing
Epidermal growth factor receptors
Gene mutations
Genes
Genetic aspects
Gynecology
Health aspects
Medical prognosis
Metastasis
Methods
Mutation
Nucleotide sequencing
Ovarian cancer
p53 Protein
Patients
Point mutation
Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Liquid biopsies from circulating tumor DNA (ctDNA) have been employed recently as a non-invasive diagnostic tool for detecting cancer-specific gene mutations. Here, we show the comprehensive gene mutation profiles of ctDNA in 51 patients with different histological subtypes of stage I–IV ovarian cancer, and their association with clinical outcomes. The ctDNA extracted from pre-treatment patients’ plasma were analyzed using Cancer Personalized Profiling by Deep Sequencing targeting 197 genes. Of 51 patients, 48 (94%) showed one or more non-synonymous somatic mutations, including TP53 (37.3%), APC (17.6%), KRAS (15.7%), EGFR (13.7%), MET (11.8%), PIK3CA (11.8%), NPAP1 (11.8%), and ALK (9.8%). The most frequently mutated genes were as follows: TP53 in high-grade serous carcinoma (66.7%), APC in clear cell carcinoma (30.8%), PIK3CA in endometrioid carcinoma (40%), and KRAS in mucinous carcinoma (66.7%). Higher cell-free (cf)DNA concentration significantly correlated with worse progression-free survival (PFS) in all patients as well as stage III–IV patients (p = 0.01 and 0.005, respectively). Further, patients with any pathogenic mutations showed significantly worse PFS (p = 0.048). Blood tumor mutational burden detected from ctDNA did not significantly correlate with the histological subtypes or survival. Collectively, clinico-genomic profiles of individual ovarian cancer patients could be identified using ctDNA and may serve as a useful prognostic indicator. These findings suggest that ctDNA-based gene profiling might help in establishing personalized therapeutic strategies.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers12113382